Topical NSAID — Throat / Mouth
Pregnancy: Use with caution — limited data; minimal systemic absorption; topical use generally considered acceptable
Benzydamine Hydrochloride
Brand names: Difflam, Difflam Forte
Adult dose
Dose: Mouth rinse (0.15%): 15 mL gargled or rinsed every 1.5–3 hours. Spray (0.15%): 4–8 sprays every 1.5–3 hours
Route: Topical (oropharyngeal)
Frequency: Every 1.5–3 hours
Max: Mouth rinse: 15 mL per use; Spray: 8 sprays per use
Topical NSAID and local anaesthetic for painful inflammatory conditions of the oropharynx: tonsillitis, pharyngitis, post-tonsillectomy pain, aphthous ulcers, oral mucositis (chemotherapy/radiotherapy). Difflam Forte (0.15%) is the standard; dilute if causes stinging.
Paediatric dose
Dose: Age-based spray/kg
Route: Topical
Frequency: Every 1.5–3 hours
Max: 4 sprays per use in children
BNFc: spray — 6–12 years 4 sprays every 1.5–3h; ≥12 years adult dose. Mouth rinse — not recommended under 12 years (swallowing risk). Do not use in infants.
Dose adjustments
Renal
No dose adjustment required (minimal systemic absorption)
Hepatic
No dose adjustment required
Paediatric weight-based calculator
BNFc: spray — 6–12 years 4 sprays every 1.5–3h; ≥12 years adult dose. Mouth rinse — not recommended under 12 years (swallowing risk). Do not use in infants.
Clinical pearls
- Useful adjunct in post-tonsillectomy pain — reduces analgesic requirement; does not increase bleeding risk at topical doses
- Oral mucositis from chemotherapy/head and neck radiotherapy: benzydamine 0.15% mouthwash reduces severity and duration (Cochrane 2014)
- Dilute 1:1 with water if burning or stinging on initial use — maintains efficacy; reduces discomfort
- Available OTC — patients can self-purchase; useful to recommend specifically for tonsillitis pending antibiotic decision
- Unlike systemic NSAIDs, topical benzydamine has no significant cardiovascular, renal, or GI systemic effects
Contraindications
- Hypersensitivity to benzydamine or NSAIDs
- Infants (choking risk with spray)
Side effects
- Oral numbness/tingling (expected — local anaesthetic effect)
- Burning sensation (dilute if occurs)
- Nausea (if swallowed)
- Photosensitivity (prolonged use — rare)
Interactions
- Minimal — negligible systemic absorption at topical doses
Monitoring
- Symptom response
- Signs of hypersensitivity
Reference: BNFc; BNF 90; BNFc; Cochrane Review (Clarkson et al. 2014) Oral Mucositis; NICE NG84. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Centor Score for Strep Pharyngitis · Infection
- Centor / McIsaac Score for Strep Pharyngitis · Throat
- Paradise Criteria for Tonsillectomy · Throat
- Centor/McIsaac Score (Pharyngitis) · Throat Infections
- Rome IV Diagnostic Criteria for Globus · Functional GI Disorders
- FeverPAIN Score for Strep Throat · Throat
Pathways
- Adult Upper Airway Obstruction (Stridor) · DAS 2015 unanticipated difficult airway; RCEM
- Epistaxis Management · ENT-UK / NICE
- Acute Otitis Media · NICE NG91 2018
- Tonsillitis and Sore Throat · NICE NG84 2018
- Benign Paroxysmal Positional Vertigo · NICE CG124 / AAO-HNS Guidelines
- Acute Rhinosinusitis · NICE NG79 2017 / EPOS 2020